Virtual Machine News Platform
NEWTON, Mass.–(BUSINESS WIRE)–Abcuro, Inc., a clinical-stage biotechnology company developing therapies for the treatment of autoimmune diseases and cancer through precise…
Inclusion Body Myositis, or IBM, is a rare degenerative muscle disease…
Abcuro draws $200M to push muscle weakness drug over the finish line FirstWord Pharma Article Source https://firstwordpharma.com/story/5934611
Abcuro, a company specializing in musculoskeletal disorders, has recently completed enrollment for its MUSCLE registration phase 2/3 clinical trial. This…
